LINC01198 and melanoma: In our study, the regulatory function of LINC01198 in vemurafenib resistance was characterized through specific knockout (CRISPR/Cas9) in melanoma cells and RNA interference (siRNA) technologies in both cell and animal experiments, which endorses strong supports for the clinical applications of CRISPR/Cas9 and RNA interference technologies targeting LINC01198.